Austin W & Greenhouse David... Net Worth

The estimated Net Worth of Austin W & Greenhouse David... is at least $62 Million dollars as of 25 August 2015. Austin David owns over 1,000 units of Palatin Technologies stock worth over $2,847,499 and over the last 21 years Austin sold PTN stock worth over $59,117,928.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Austin David PTN stock SEC Form 4 insiders trading

Austin has made over 160 trades of the Palatin Technologies stock since 2006, according to the Form 4 filled with the SEC. Most recently Austin sold 1,000 units of PTN stock worth $13,000 on 25 August 2015.

The largest trade Austin's ever made was selling 7,000,000 units of Palatin Technologies stock on 14 February 2013 worth over $910,000. On average, Austin trades about 189,306 units every 16 days since 2003. As of 25 August 2015 Austin still owns at least 1,991,258 units of Palatin Technologies stock.

You can see the complete history of Austin David stock trades at the bottom of the page.

What's Austin David's mailing address?

Austin's mailing address filed with the SEC is C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK, NY, 10022.

Insiders trading at Palatin Technologies

Over the last 22 years, insiders at Palatin Technologies have traded over $3,929,269 worth of Palatin Technologies stock and bought 390,692 units worth $374,235 . The most active insiders traders include Austin W & Greenhouse David..., Partners L P/Ilbiotechnolog... und Carl Spana. On average, Palatin Technologies executives and independent directors trade stock every 76 days with the average trade being worth of $128,497. The most recent stock trade was executed by Stephen T Wills on 1 August 2024, trading 4,999 units of PTN stock currently worth $8,298.

What does Palatin Technologies do?

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy

Complete history of Austin David stock trades at Amtech Systems, Broadwind Inc, Cellectar Biosciences Inc, Ceva, Clean Diesel Technologies, Cyclacel Pharmaceuticals Inc, Image Sensing Systems, Inovio Pharmaceuticals Inc, Iteris, Lightbridge Corp, Liveperson Inc, ParkerVision, PFSWEB Inc, Plug Power Inc, Tandy Leather Factory Inc, Ultra Clean Hldgs Inc, Graham und Palatin Technologies

Palatin Technologies executives and stock owners

Palatin Technologies executives and other stock owners filed with the SEC include:

• Carl Spana,
  President, Chief Executive Officer, Director
• stephen Wills,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer, Secretary
• Dr. Carl Spana Ph.D.,
  Co-Founder, Pres, CEO & Director
• Stephen T. Wills CPA, CPA, MST,
  CFO, COO, Exec. VP, Treasurer & Sec.
• Angela Rossetti,
  Independent Director
• Arlene Morris,
  Independent Director
• Anthony Manning,
  Independent Director
• Joseph Hull,
  Independent Director
• Alan Dunton,
  Independent Director
• Robert deVeer,
  Independent Director
• John Prendergast,
  Independent Chairman of the Board
• Robert Jordan,
  Sr. VP of Program Operations
• John Dodd Ph.D.,
  Sr. VP of Preclinical Devel.
• James E. Hattersley,
  Sr. VP of Bus. Devel.
• Dr. Michael B. Raizman M.D.,
  Chief Medical Officer
• Stephen A. Slusher Esq.,
  Chief Legal Officer
• Burns McClellan,
  VP of Investor Relations
• Zola P Horovitz,
  Director
• Robert I Taber,
  Director
• Partners L P/Ilbiotechnolog...,
  
• Austin W & Greenhouse David...,
  10% owner
• Errol B Desouza,
  Director
• Trevor Hallam,
  Exec. VP Res. & Dev.
• Perry B Molinoff,
  Exec. VP Research and Devel.
• Investments Lpproquest Asso...,
  
• Joseph Edelman,
  10% owner